This invesigator-initiated, multicentre Australian and New Zealand study has been designed to provide evidence to help nephrologists and their CKD patients better determine whether Oxpentifylline (Trental®) administration will safely and effectively treat erythropoietin- or darbepoietin-resistant anaemia. This evidence concerns the gene EPO and anemia (phenotype).